Evidence map›Paper›PMID 41768867›Full record

ArticleJournal of hematology2026

A Rare Presentation of T-cell Prolymphocytic Leukemia With Abnormal Uterine Bleeding.

Zeinab Nasser, Sarine Tahmazian, Moneb Bughrara, Batoul Nasser, Aula Ramo, Vrushali Dabak

Abstract readCase Reports
In one paragraph

Article in Journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zeinab NasserDepartment of Hematology and Oncology, Henry Ford Hospital, Detroit, MI 48202, USA.
Sarine TahmazianDepartment of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202, USA.
Moneb BughraraDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Batoul NasserDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Aula RamoDepartment of Hematology and Oncology, Henry Ford Hospital, Detroit, MI 48202, USA.
Vrushali DabakDepartment of Hematology and Oncology, Henry Ford Hospital, Detroit, MI 48202, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare and clinically aggressive T-cell neoplasm, which is composed of lymphoid cells that are of post-thymic T-cell origin. This is a case of a 57-year-old female with no significant medical history, who presented with a 4-month history of facial swelling, peripheral edema, dyspnea, palpitations, and abnormal uterine bleeding (AUB). A complete blood count demonstrated lymphocytosis, and a computed tomography (CT) scan of the abdomen and pelvis showed diffuse lymphadenopathy, splenomegaly, and uterine fibroids. A bone marrow biopsy confirmed the presence of T-PLL with a subsequent endometrial biopsy showing atypical lymphoid proliferation consistent with T-PLL. The patient was started on alemtuzumab for T-PLL treatment. This case demonstrates a rare presentation of T-PLL with endometrial involvement, which may have contributed to the patient's postmenopausal uterine bleeding. Recognition and evaluation of disease infiltration require prompt clinical assessment to reduce the morbidity and mortality associated with T-PLL.

Indexed as

Abnormal uterine bleedingAlemtuzumabAnti-CD52 therapyEndometrial biopsyLymphadenopathyLymphocytosisT-cell prolymphocytic leukemia

Identifiers

PMID41768867
PMCPMC12948471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.